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Abstract: The COVID-19 pandemic caused by highly-infectious virus namely severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in infection of millions of 
individuals and deaths across the world. The need of an hour is to find the innovative solution for 
diagnosis, prevention, and cure of the COVID-19disease. Nanotechnology is emerging as one of the 
important tool for the same. In the present review we discuss the applications of nanotechnology-
based approaches that are being implemented to speed up the development of diagnostic kits for 
SARS-CoV-2, development of personal protective equipments, and development of therapeutics of 
COVID-19 especially the vaccine development. 
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Coronavirus disease 2019 (COVID-19) is an infectious disease caused by virus namely severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus belongs to Coronaviridae 
family. SARS-CoV-2 is an enveloped virus with an average diameter of 60–140 nm and contains a 
single-stranded, positive-sense RNA [1]. The genome of SARS-CoV-2 is around 30 Kb, and it 
encodes for several accessory proteins and four structural proteins: spike (S), envelope (E), 
membrane (M), and nucleocapsid (N) (Figure 1) [2].  
 
Figure 1. Structure of SARS-CoV-2. 
The virus, after being first discovered in Wuhan, China, has spread to all over the world and has 
caused over 1.2 million deaths and over 49.7 million total cases of infection as of 26 July 2021 [3]. 
Respiratory droplets released during coughing and sneezing and direct contact with infected 
individual transmit SARS-CoV-2 to healthy individual [4]. The virus mainly affects the respiratory 
system and can cause acute respiratory distress syndrome and multiple-organ failure, thus leading to 
patient's death [5–6]. COVID-19 affects many organs of the body, so people with COVID-19 may 
have a wide spectrum of symptoms. Symptoms and signs of the illness may be important to help 
them and the healthcare staffs they come into contact with know whether they have the disease. Most 
infected people with SARS-CoV-2 develop mild to moderate illness and recover without 
hospitalization and specialized treatment. The older people and those with medical complications 
such as chronic respiratory disease, cardiovascular disease, cancer, and diabetes are more vulnerable 
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and more likely to develop serious illness. Most common symptoms, less common symptoms and 
serious symptoms associated with SARS-CoV-2 infection are represented in Figure 2. 
 
Figure 2. Most common symptoms, less common symptoms and serious symptoms 
associated with SARS-CoV-2 infection. 
Mutations in the genome of SARS-CoV-2 have given rise to various new variants reported from 
many countries namely Brazil, India, South Africa, and the United Kingdom. These new variants are 
deadlier with higher transmission rate as compared to original strains. Moreover, these variants 
increase the chance of reinfection and have negative impact on the effectiveness of vaccines-induced 
immunity [7]. To prevent the spread of the COVID-19, the officials of the countries across the world, 
enforced various strategies such as suspension of traveling, prolonged lockdown, quarantine, and 
mandatory facial protection. Such measures indeed decreased the spread of the viral infection, but 
the limitations of these measures make the unsustainable in a long run due to the involvement of 
major socioeconomic cost [8–10]. Therefore, long-term innovative solution is need of an hour to 
fight the virus due to limited economic resources. Nanotechnology is one such innovative tool that 
has emerged with higher success rate in the field of therapeutics and diagnosis and imaging of 
various diseases [11]. Nanotechnology approaches normally utilizes nanoscale particles (i.e., 
nanostructures) falling under 1 to 100 nm range. But some authorities extend the definition of 
nanostructures to include molecules up to 1000 nm size [12]. Nanostructures' small size, large 
surface to volume ratio, surface charge, bioavailability, biodegradability, biocompatibility, and ability 
to be modified through surface modification impart nanomaterials unique physicochemical properties 
that made nanomaterials attractive for biomedical application [13–15]. Various types of 
nanostructures and nanomaterials including metal nanostructures, transition metal oxide 
371 
AIMS Microbiology  Volume 7, Issue 4, 368–398. 
nanostructures (emerging nanomaterials that have shown excellence in various fields),carbon-based 
nanostructures (carbon nanotubes, graphene and graphene oxide), lipid-based nanostructures (nanosized 
micelles/vesicles),quantum dots, and polymeric nanostructures are being used as theranostic (i.e., 
therapeutic and diagnostic) agents against viral infections [16]. The last few years have seen 
increasing use of nanostructures for the treatment of viral infections, such as HIV, hepatitis B virus, 
Hepatitis C virus, H1N1, herpes simplex virus, human papilloma virus, Zika virus, respiratory 
syncytial virus, and human norovirus [17–19]. During the start of COVID-19 pandemic biomedical 
researchers proposed that nanotechnology may play an important role in managing the COVID-
19pandemic [20–24]. The prediction was surely found to be true as can be gauged from the related 
reports emerging across the globe. For example, scientists have taken advantage of nanotechnology 
to develop biosensors in order to detect SARS-CoV-2 in patient samples, and to develop antiviral 
products that can be implemented to prevent the transmission of SARS-CoV-2 [25]. Along with this, 
nanotechnologies have also been successfully used and are being used to develop therapeutic agents 
and vaccines against SARS-CoV-2 [25]. In the present review we discuss the nanotechnology-based 
approaches that are being utilized to mitigate COVID-19 disease. The first section the review 
summarizes recent studies that have implemented nanotechnology based approaches to speed up the 
development of diagnostic kits for SARS-CoV-2. The second section discuses the use of 
nanotechnology based approaches in the development of personal protective equipments such as face 
masks, sanitizers, surface coatings, etc. in order to prevent the spread of virus. Finally, the third 
section of the review discuses the application of nanotechnology in therapeutics of COVID-19 
especially in the field of vaccine development against SARS-CoV-2. 
 
Figure 3. Functional aspects of nanotechnology against COVID-19 pandemic. 
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2. Role of nanotechnology in the detection of SARS-CoV-2 
Despite the development of new vaccines against COVID-19 (developed by the companies such 
as Pfizer, Moderna, Johnson & Johnson, Bharat Biotech International Limited, and Oxford-
AstraZeneca), the importance of early rapid detection to control and prevent COVID-19 cannot be 
further emphasized due to the need to isolate the infected person from rest of the people living in the 
vicinity to prevent spread of the infection to the still unvaccinated population. There are mainly two 
types of approaches to detect the presence of SARS-CoV-2. One is the diagnostic approach that 
involves either detection of viral nucleic acid (i.e. molecular test/assay) or viral antigens (i.e. antigen 
test). The second one is serological approach that detects the presence of immunoglobulin G (IgG) and/or 
immunoglobulin M (IgM) or total antibodies produced in a person infected with SARS-CoV-2 [26]. 
World Health Organization (WHO) has mandated reverse transcription polymerase chain reaction (RT-
PCR) as the standard test to diagnose SARS-CoV-2 in patient samples. But RT-PCR is not available 
everywhere due to economic constraints and the lack of infrastructure, and its results could take from 
few hours to many days due to insufficient human or lab capacities [27]. This time lag can lead to the 
spread of COVID-19 to a wider community and loss of precious life that could have been saved only 
if the person had been diagnosed earlier. In these circumstances, point-of-care testing that should be 
reliable, cheap, and fast and should provide results within short time window has become need of an 
hour for the prevention of COVID-19 pandemic. Because nanostructures are of similar size to that of 
SARS-CoV-2, nanostructures can bind to the virus and thus can be utilized for therapy and detection 
of COVID-19 infection [28]. The use of nanotechnology and nanostructures in order to develop 
diagnostic and serological tests for COVID-19 infection is increasing greatly [29–32]. Nanomaterials 
can be functionalized with biomolecules to detect and amplify signal in colorimetric detection of 
pathogens [33], and large surface area of nanostructures increases capture efficiency of, and thus 
sensitivity of a biosensor [34]. Similarly, the functionalization of nanostructures with antibodies 
against SARS-CoV-2 increases sensitivity and affinity of biosensor for the analyte and enhances 
signals (e.g. electrochemical, electrochemiluminescent, magnetic, or optical signals) thus making the 
detection of target molecule and of COVID-19 infection easier [35]. Table 1 lists the examples of 
nanomaterials that are being used to devise biosensor to detect SARS-CoV-2.  
Many biosensing techniques for the detection of SARS-CoV-2 have utilized gold nanostructures 
(Table 1). Because these nanostructures are easier to synthesize, biocompatible, and 
physicochemically stable [36]. Karami and coworkers [37] devised a colorimetric detection 
technique for SARS-CoV-2 RNA by attaching spherical nucleic acids to the surface of gold 
nanostructures. The biosensing system included a 4-nucleotide palindromic linker to probe the E 
gene region of SARS-CoV-2 RNA. The assay was comparable in sensitivity to the real-time RT-PCR.  
In an interesting approach, Sil and group [38] designed a type of qualitative immunoassay 
named as rapid flow-through dot-blot immunoassay. The group used gold nanostructures 
functionalized with antibodies to detect SARS-CoV-2 specific IgG in human serum, with sensitivity 
and specificity of 98.8% and 98%, respectively. 
Ventura et al. [39] constructed gold nanostructures-based biosensor to detect SARS-CoV-2 in 
nasal and throat swabs. The researchers prepared three types of gold nanostructures, each 
functionalized with antibodies against spike, envelope, or membrane surface proteins of SARS-CoV-2. 
The three types of gold nanostructures were mixed in equal (1:1:1) ratio to make a colloidal solution, 
when interacted with virus particles, gave red color, which could be measured at 560 nm to quantify 
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viral load. The detection method is a faster and better alternative to the RT-PCR method, because it 
does not require preparatory steps, such as RNA extraction and amplification. Further, the detection 
technique can quantify the viral load and severity of the viral infection, because the technique detects 
viral particles rather than SARS-CoV-2 RNA.  
Moitra et al. [40] also utilized gold nanostructures and developed a colorimetric assay to detect 
SARS-CoV-2 in patient samples. The researchers functionalized gold nanostructures with thiol-
modified antisense oligonucleotides specific for N-gene of SARS-CoV-2. In the presence of target 
RNA sequence of SARS-CoV-2, the functionalized gold nanostructures agglomerated, which could 
be detected by UV-Visible absorbance spectroscopy and other techniques including transmission 
electron microscopy, and hyper spectral microscopy. Further, when RNA samples with functionalized 
gold nanostructures were treated with enzyme RNase H at 65 ℃ for 5 min, the samples were 
precipitated that could easily be seen by naked-eye, thus avoiding the need for any sophisticated 
instrument to detect SARS-CoV-2. The bioassay was selective for SARS-CoV-2, because it did not 
produce any distinct change in absorbance in the presence of Middle East respiratory syndrome 
coronavirus (MERS-CoV) RNA; the limit of detection was 0.8 ng µL
−1 
for SARS-CoV-2.  
Gold, silver and other nanostructures can show plasmonic effects that when combined with surface-
enhanced Raman scattering (SERS) spectroscopy or surface-enhanced infrared absorption (SEIRA) 
spectroscopy can be used to detect small analyte at a very low concentration [41] and in the 
construction of point of care devices for virus detection [42,43]. Jadhav and coworkers [44] exploited 
surface-enhanced Raman spectroscopy (SERS) by coupling it with a microfluidic platform that 
contained silver or gold nanostructures coated carbon nanotubes micro channels. Silver and gold 
nanostructures acted as plasmonic materials that could increase Raman intensity of even traces of 
SARS-CoV-2 in samples (eyes, nasal, throat, and saliva swabs) and helped in rapid of detection of 
the virus in the sample [44]. In another surface-enhanced Raman spectroscopy based lateral-flow 
immunoassay, Liu et al. [45] showed that using complete Ag shell on SiO2 core (i.e. core-shell 
nanostructures) resulted in 800 times increase in the sensitivity of biosensor for the detection of anti-
SARS-CoV-2 IgM/IgG in comparison with that of standard gold nanostructures-based lateral-flow 
immunoassay method. 
Recently, Qiu and coworkers [46] developed a dual-functional ultrasensitive biosensor based on 
plasmonic effects (plasmonic photo thermal effect and localized surface plasmon resonance) to detect 
SARS-CoV-2, with a detection limit of 0.22 × 10
−12
 M. The biosensor included two-dimensional gold 
nanoislands, a type of nanostructure, functionalized with complementary DNA, which when 
hybridized to RNA of SARS-CoV-2 could detect the presence of the virus. 
Zhu et al. [47] devised a new diagnostic assay based on reverse transcription loop-mediated 
isothermal amplification method in combination with a nanostructure-based lateral flow biosensor to 
diagnose COVID-19 in patients. Zhu's group reported 100% sensitivity for the diagnostic assay, after 
analyzing 33 oropharynx swab samples from COVID-19 patients. The assay also showed very high 
specificity of 100% for COVID-19 negative samples. The assay was very fast and took only an hour 
to complete. 
Wang's group [48] have recently exploited modified selenium nanostructures to prepare a lateral 
flow immunoassay kit that can detect anti-SARS-CoV-2 antibodies (IgG and IgM) in human serum, 
with naked-eye in only 10 minutes. The researchers tested the bioassay in 90 COVID-19-diagnosed 
patients and 263 non-infected controls and reported 93.33% sensitivity and 97.34% specificity. 
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Cobalt-functionalized TiO2 nanotubes (Co-TNTs) was used by Vadlamani et al. [49] to 
synthesize a non-expensive and highly sensitive electrochemical sensor that can detect the 
receptor-binding domain (RBD) domain of spike protein of SARS-CoV-2 in the concentration 
range of 14 to 1400 nM. 
In the place of commonly used gold nanostructures in biosensor to detect SARS-CoV-2, some 
research groups used carbon nanotubes [41,48], graphene [49,50], and graphene-based (graphene 
oxide or reduced graphene oxide) [51] nanomaterials due to carbon nanotube's and graphene's high 
conductivity and biocompatibility [52,53], and benefit of lower cost [29]. Further, the modification 
of graphene’s surface with functional groups imparts the biosensor with very high sensitivity and 
ability to recognize biological molecule [54]. For example, Seo and colleagues [49] developed a 
graphene field-effect transistor (FET)-based biosensor device for the detection of SARS-CoV-2 in 
clinical samples. In this sensor, the researchers coated graphene sheets of field-effect transistor with a 
specific antibody against SARS-CoV-2 spike protein. The biosensor could detect the SARS-CoV-2 
spike protein at concentration as low as of 1 fg/mL in phosphate-buffered saline (PBS) and of 100 fg/mL 
in clinical transport medium. The biosensor could further detect SARS-CoV-2 in clinical samples 
with the limit of detection of 2.42 × 10
2
 copies/ml. The sensor can discriminate between SARS-CoV-2 
antigen protein and MERS-CoV antigen protein, thus restricting any chance of cross-reactivity with 
MERS-CoV [49]. Li and collaborators [50] achieved amplification-free detection of SARS-CoV-2 
RNA via a biosensor that included graphene field-effect transistor decorated with morpholino-
modified gold nanostructure. The tests showed very low limit of detection of SARS-CoV-2 RNA in 
phosphate buffer saline (0.37 fM), throat swab (2.29 fM), and serum (3.99 fM); and the test took 
only 2 minutes to ascertain the SARS-CoV-2 infection in clinical throat swabs sample [50]. 
In another study, Huang et al. [55] developed lateral-flow assay based on colloidal gold 
nanostructures to detect IgM antibody against SARS-CoV-2 in serum samples of patients through 
immunochromatography. This assay can give results in only 15 minutes, and it needs only 20 µL of 
serum sample for each test in comparison with RT-PCR test that needs around 100 µL of the sample. 
The sensitivity and specificity of the nanostructures based lateral-flow assay were 100 and 93.3% 
respectively. 
Similarly, Mertens and group [56] have prepared a diagnostic strip named as Ag Respi-Strip, 
which is based on the principles of immunochromatographic assay. The diagnostic strip utilized anti-
SARS-CoV-2 (nucleocapsid protein) antibodies conjugated with colloidal gold nanostructures. The 
sensitivity and specificity of the test were 57.6% and 99.5%, respectively.  
Wen et al. [57] reported a rapid point-of-care (POC) lateral-flow immunoassay based on 
colloidal gold nanostructures to diagnose SARS-CoV-2. The researcher’s functionalized gold 
nanostructures to anti–human IgG, sprayed it onto the pre-treated conjugate pad that already 
contained SARS-CoV-2 nucleocapsid protein, and employed a change in color as a marker for the 
presence of viral protein in patient samples. The sensitivity and specificity of the assay were 69.1% 
and 100%, respectively. 
Shan and coworkers [58] developed a novel biosensor that detects SARS-CoV-2 from exhaled 
breath. The sensor is based on the principle that during viral infection cells produce—due to 
interaction between host cells and virus—volatile organic compounds, which are present in the 
exhaled breath of a patient and thus can be used as a biomarker for the detection of a disease [59]. 
The sensor constructed by Shan's group (2020) [60] included a sensing layer composed of organic 
ligands and gold nanostructures. When exposed to volatile organic compounds present in exhaled 
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breath, the sensing layer shrinks or swells and causes a volume change in the nanomaterial film that 
was captured by change in electric resistance. Although this technique needs to be validated in a 
larger cohort size, it can still be used for the rapid screening of COVID-19. 
Fabiani et al. [54] have developed an electrochemical immunoassay for rapid detection of 
SARS-CoV-2 in saliva samples. Screen-printed electrodes used in the assay were based on carbon 
black nanomaterial, which due to its cost-effectiveness, electro catalytic properties, and 
biocompatibility is gaining popularity in the designing of electrochemical biosensors [61]. The assay 
could detect spike protein or nucleocapsid protein of the SARS-CoV-2. A detection limit of 100 fg/ml 
was found for nasopharyngeal swab samples from COVID-19 patients. 
In a very interesting approach, Vaquer et al. [62] devised a non-invasive method for detecting 
SARS-CoV-2 proteins trapped in surgical face masks. The researchers used antibody-decorated gold 
nanostructures, which when comes in contact with SARS-CoV-2 antigens trapped in surgical face 
masks produce colorimetric signal; the whole assay takes only less than 10 minutes to complete. 




Detection of molecule Limit of detection Study 
Gold nanostructures Spike protein 5 μg·mL–1 [63] 
Gold nanostructures Spike protein 80 copies mL
−1
 in contaminated water [64] 
Gold nanostructures anti-SARS-CoV-2 IgG Semi-quantitative [37] 
Gold nanostructures RNA 4 copies/μL [65] 
Gold nanostructures N gene and E gene 300 copies/µL of E gene; 225 copies/µL of 
N gene 
[66] 
Gold nanostructures Viral proteins of 
SARS-CoV-2 trapped in 




Gold nanostructures RNA 50 RNA copies per reaction [67] 
Gold nanostructure 16S rRNAs; N gene (Not Reported) [68] 
Gold nanostructures anti-SARS-CoV-2 IgG 
antibodies 
3.2 nM [69] 
Gold nanostructures N gene 0.18 ng/μL [39] 
Gold nanostructures Viral particles Viral loads corresponding to Ct = 36.5 [38] 
Gold nanostructures RNA 10 copies/μL [70] 
Gold nanostructures anti-SARS-CoV-2 IgM (Not reported) [55] 
Continued on next page 
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Nanomaterial/nanostructures Detection of molecule Limit of detection Study 
Gold nanostructures Highly conserved 
nucleoprotein 
250 pg/mL [56] 
Gold nanostructures anti-SARS-CoV-2 IgG (Not reported) [57] 
Gold nanostructures Volatile organic 
compounds from breath 
(Not reported) [58] 
Gold Nano star Spike protein and the 
virus 
130 fg/mL for antigen and 8 particles/mL 
for virus 
[71] 
Gold nanoislands RNA 0.22 pM [44] 
Gold nanoisland films RNA 2.98 copies μL-1 [72] 
Gold nanostructures and 
spherical nucleic acid 
RNA (Not reported) [73] 
Gold nanostructures and 
spherical nucleic acid 
RNA Six copies of ssDNA per reaction [36] 
Gold nanostructures and 
graphite 
Spike protein 229 fg mL-
1
 [74] 
Gold and silver 
nanostructures 
Spike protein 0.77 fg mL
−1
 in PBS; 6.07 fg mL
−1
 in 
saliva; 7.60 fg mL
−1
 in serum; and 0.10 pg 
mL
−1
 in blood 
[75] 
(Not Reported) SARS-CoV-2 total 
antibody 
(Not Reported) [76] 
Gold-platinum core-shell 
nanostructures 







effect transistor (G-FET) 
sensor 
RNA 0.37 fM in PBS; 2.29 fM in throat swab; 






10 ng/mL for IgM and 5 ng/mL for IgG [78] 
Lanthanide-doped 
nanostructures 
anti-SARS-CoV-2 IgG (Not Reported) [79] 
Selenium nanostructures anti-SARS-CoV-2 IgM 
and IgG 
20 ng/mL for IgM and 5 ng/mL for IgG [46] 
Au/Ag coated carbon 
nanotubes 
Live virus (Not Reported) [41] 
Continued on next page 
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Nanomaterial/nanostructures Detection of molecule Limit of detection Study 
Europium-chelate-based 
fluorescent nanostructures 
RNA 1,000 TU (transduction units) mL−1 [80] 





(Not Reported) Total antibody (IgA, 
IgM, 
and IgG) against 
SARS-CoV-2 
(Not Reported) [81] 
Cobalt functionalized-TiO2 
nanotube 
RBD domain of S 
protein 
~0.7 nM [47] 
Carbon black Spike (S) protein or 
Nucleocapsid (N) 
protein 
19 ng/mL for S protein; 8 ng/mL for N 
protein 
[60] 
Carbon nanotubes RNA 6.4 copies/μL in PBS and 9.2 copies/μL in 
50% human saliva 
[48] 
Graphene Spike protein 1.6 × 10
1
 pfu/mL in culture medium; 2.42 × 
10
2
 copies/mL in clinical samples; 1 fg/mL 
in phosphate-buffered saline; 100 fg/mL in 
clinical transport medium 
[49] 
Graphene Spike protein ∼3.75 and ∼1 fg/mL in artificial saliva and 




Antibodies to spike S1 





 M for spike S1 protein and 16.9 
× 10
−15
 M receptor‐binding‐domain 
[51] 
Quantum dot Antibodies 17.5 pM for nucleocapsid antibody and 24.4 
pM for S1 antibody 
[83] 
Quantum dot Nano beads SARS-CoV-2 total 
antibody 
(Not Reported) [84] 
Enzyme-DNA hybrid Nano 
complexes 
RNA ~8 RNA copies/μL [85] 
Streptavidin coated polymer 
nanostructures 
ORF1ab and N gene 12 copies per reaction [45] 
Aggregation-induced 






 for IgM; 0.125 μg mL–1 for IgG [86] 
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3. Role of nanotechnology in preventing transmission of SARS-CoV-2 
To prevent spread of COVID-19, social distancing, mask wearing, and hand sanitizing are being 
implemented. Similarly, products, such as face masks, face shields, disinfectants, and sanitizer are 
being used to minimize the spread of SARS-CoV-2 infection in the community. Although face masks 
protect the person from catching the virus, they do have certain limitations: (1) medical masks 
recommended for health workers are for single-use only; (2) face masks act only as a barrier to virus 
transmission, they do not inactivate virus; (3) N95 face masks provide only 95% filtration efficiency 
for particles more than 0.3 micron size [87], thus particles that are less than 200 nm, such as SARS-
CoV-2 can pass through them. Nanotechnology-based solutions are being utilized to improve upon 
such limitations, because nanostructures can infiltrate viral coronae, can bind to the virus and prevent 
its attachment to the host cell surface during entry, and can inhibit viral replication thus preventing 
spread of infection [88,89]. The embedding of nanomaterials can provide antiviral properties to (i.e., 
viral inactivation capability) and improve filtration ability of protective clothing [90]. Further, 
nanostructures can persist for longer duration and can be effective at a low concentration, which 
makes their use in disinfectants to sterilize air, physical surfaces, or skin beneficial [91]. 
Nanostructures can prevent spread of virus by various mechanisms: They can interact with the viral 
glycoproteins, thus prevent binding and penetration of viral glycoproteins to the host cell [91]; and 
on exposure to UV radiation, the nanostructures can generate reactive oxygen species that oxidize the 
viral membrane or envelope [91,92]. Table 2 has listed some nanotechnology-based products that 
have claimed to prevent SARS-COV-2 transmission in community. The products are using various 
nanomaterials, including graphene, copper oxide, titanium dioxide, and silica, nanene (a type of 
graphene) in products, such as face masks, face shields, fabrics, packaging material, air filters, and 
coating (Table 2).  
Table 2. Products based on nanotechnology to prevent SARS-CoV-2 transmission. 
Products Nanostructures Company/Organization Country 
Graphene Mask Graphene Flextrapower Inc USA 
Nano shield CuO Nanoveu Inc Australia 
Virucidal Graphene-Based 
Composite Ink 
Graphene and Ag ZEN Graphene Solutions Ltd Canada 
Guardian G-Volt 
respiratory mask 
Graphene LIGC Applications Ltd USA 
Co-Mask Graphene Directa Plus PLC UK 
Antiviral fabrics Cu Promethean Particles Ltd UK 
MVX Nano MaskTM TiO2 MVX Prime Ltd UK 
Nano Silver Sanitizer Ag Shepros Sdn. Bhd. Malaysia 
Continued on next page 
379 
AIMS Microbiology  Volume 7, Issue 4, 368–398. 
Products Nanostructures Company/Organization Country 
ReSpimask® VK (Virus 
Killer) 
CuO Respilon Group S. R. O. Czech Republic 
Diamond Face Mask Diamond Master Dynamic Limited China 
NANOHACK CuO Copper 3D Antibacterial Innovations Chile 
G1 Wonder Face Masks Graphene Nanomatrix Materials India 
Nanocoating (Not reported) Nanoksi Finland Finland 
Nanofense Ag Applied Nanoscience Inc. USA 
Transparent stretchable PVC 
film for use in packaging 
Silver and silica Alpes and Nanox Brazil 
Graphene Face Mask Graphene Medicevo USA 
Nanofiber Membranes (Not reported) BYU’s College of Engineering with 
Nanos Foundation 
USA 
ZEN’s Virucidal Ink Graphene ZEN Graphene Solutions Ltd. Canada 
Nano-coated air filters (Not reported) University of Houstan USA 
Graphene Enhanced 
Protective Face Mask 
Nanene Versarien UK 
Nano Textile Coating (Not reported) IIT Madras and Muse India 
Rubber, paint, coating, and 
cosmetics 
ZnONPs Brüggemann Germany 
Source: Nanotechnology Products Database (2021) [93]; Nanotechnology in battle against 
coronavirus (n.d.) [94]. 
The nanostructures impregnated to the face masks can kill viral particles remained in the masks 
without altering filtering properties of face masks and thus can ensure further reduction in risk of 
viral infection due to incorrect handling and disposal of face masks [95]. Very recently, a research 
team from Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea has 
developed a nanotechnology-based filter that retains excellent filtering efficiency even after washing 
for more than 20 times [96]. The use of such filters can solve the problem of shortage of face masks. 
The researchers used orthogonal nanofibers and insulation block electrospinning process to create the 
face mask. According to the scientist, the nanofiber filter is water-resistant and shows 94% filtration 
efficiency after 20 repeated bactericidal tests with ethanol [96]. 
Similarly, Queensland University of Technology-based research team has constructed 
biodegradable face masks based on nanotechnology [97]. The face mask is made of cellulose 
nanofiber obtained from plant waste and agricultural waste. The breathable nanocellulose material 
can filter particles smaller than 100 nm, which is the size of several human viruses, including SARS-
CoV-2. 
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Wakamono, which is a Vietnam based company working in field of nanotechnology, has 
announced that it has created the world's first anti-coronavirus surgical masks [98]. The mask is 
made of GECIDE fabric technology that utilizes organic nanostructures and can inactivate SARS-
CoV-2 up to 99%. The mask is also effective against influenza A H1N1 and poliovirus I [98]. 
Tremiliosi et al. [99], in a recent study, functionalized polycotton fiber with silver 
nanostructures by the pad-dry-cure method. The composite fibers were found to inhibit the SARS-
CoV-2 only after two minutes incubation. The fiber has the potential to be used in textile materials 
that can stop the transmission of SARS-CoV-2.  
Jeremiah and group [100] have recently showed the antiviral effect of silver nanostructures on 
SARS-CoV-2 viral suspension. This study showed that silver nanostructures can be used as surface 
coating to deactivate SARS-CoV-2 and prevent their further transmission. The angiotensin-
converting enzyme 2 (ACE2) receptor-expressed by various organs, such as liver, heart, kidney, 
lungs, etc. [101] plays an important role in the entry of SARS-CoV-2 into host cells [102]. But, the 
receptor can also play protective role in acute lung injury [103]; this fact prompted Aydemir and 
Ulusu [104] to propose that nanomaterials coated with ACE2 can be used to prepare clothes, mask, 
gloves, and other protective covers to sequester virus and block their entry into the host. 
Products based on graphene and its derivatives (graphene oxide, reduced graphene oxide, and 
graphene quantum dots) as argued by Raghav and Mohanty [105], have the potential to be used 
against SARS-CoV-2 infection. The mono- or multi-layers graphene and its derivatives can be 
applied either as coating on fabrics to keep them dry to prevent aerosol transmission of SARS-CoV-2, or 
as a mist spray and cleaning solution to sanitize the infected surfaces of an object or human body [105]. 
The antiviral effect of graphene oxide and its Nano composite on feline coronavirus, an enveloped 
virus, has shown by Chen et al. [106]. Similar application of graphene oxide against SARS-CoV-2, 
also an enveloped virus, can be tried by using coatings of graphene oxide on clothes to make 
antiviral protective products.  
De Maio and group [107] showed that polyurethane and cotton both used in personal protective 
equipment when functionalized with graphene nano platelets or graphene oxide can entrap SARS-
CoV-2. When the SARS-CoV-2 culture was incubated with or filtered through the functionalized 
polyurethane and cotton material, the capacity of the virus to infect Vero cells (African green monkey 
kidney epithelial cell) decreased. However, the concentration range of graphene oxide (0.06–0.5 
mg/mL) used in the experiment is not realistic for the purposes of therapeutics against SARS-CoV-2. 
Unal's group [112] in different experiment via molecular docking method and in vitro method 
showed that graphene oxide sheets could decrease infectivity of SARS-CoV-2 by interacting with its 
viral spike protein. The efficacy of graphene oxide sheets were also shown to be persisted when 
different mutations were present in the viral spike protein [112]. 
The Guardian G-Volt Respiratory mask by LIGC Applications employs a graphene filtration 
system [109]. This mask is 99% effective against particles over 0.3 micrometers, in comparison with 
N95 respirator mask that can only blocks 95 per cent of particles over 0.3 micrometers, thus having 
the potential to prevent SARS-CoV-2 transmission [113].  
Coating of silver nanocluster/silica composite onto disposables facial FFP3 masks (3M
TM
) have 
been shown to reduce the titer of SARS-CoV-2 to zero [114]. The application of the antiviral coating 
can be extended to other surfaces, such as ceramic, glass, and metallic to prevent the spread of the 
virus in public areas [115]. 
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Kumar's group [96] has created a photoactive antiviral mask, which was coated with hybrid of 
copper nanostructures and shellac, a hydrophobic biopolymer. As per researchers, under the sunlight 
the temperature of the mask could reach >70 ℃, which in turn give rise to free radicals that can 
disrupt the membrane of virus-like particles and give the mask self-sterilization capability. The mask 
can be a great asset against protection from SARS-CoV-2 and COVID-19 pandemic. 
Although the COVID-19 pandemic is witnessing the emergence of many commercial products (e.g., 
face masks, coatings, etc.) that claim to be using nanostructures and be effective against SARS-CoV-2, 
such claims must be duly scrutinized to save consumer from any harm from potential exposure to the 
virus. For example, Blevens et al. [112] evaluated the claims of 40 cloth face masks that claimed to 
be using either silver or silver nanostructures and to have antiviral properties. The researchers 
concluded that the claims made by companies on using nanostructures in face masks are not always 
true, and further the filtration efficiency might not up to the standard certification requirement. The 
researchers proposed stricter regulation of products by governmental agencies to ensure efficacy of 
the face masks for safety of the consumer [112]. Similarly, there is a persisting concern among 
scientist due to the long-term effect of nanomaterial application in protective fabrics to the 
environment and to the person wearing the protective covering [86]. Further, the widespread uses of 
masks have inevitably accelerated the release of nanoplastics, micro plastics, and chemical pollutants 
from disposable masks to the environment [113,114]. If the scientists could combine use of 
nanomaterials in masks with new nanotechnology that degrade micro plastics such as that shown by 
Kang's group [115], then it would be better for the environment and for people's health. Another 
approach to decrease the toxicity of metal nanostructures to the person using protective fabrics as 
suggested by Sportelli et al. [123] in a review article was to impregnate copper salt along with 
nanomaterials into the masks, personal protective clothing, and fabrics. 
4. Role of nanotechnology in therapeutics development against SARS-CoV-2 
Multiple research groups all over the world are working on therapeutic agents to prevent 
COVID-19. For example, as of 31 July 2021, more than 200 vaccines (including both in clinical and 
preclinical evaluation) against SARS-CoV-2 are in development [116]. Among these, seven (BNT162b2 
or Comirnaty by Pfizer–BioNTech, mRNA-1273 by Moderna, AZD1222 by Oxford–AstraZeneca, 
Ad26.COV2.S by Janssen, Covishield by Serum Institute of India, BBIBP-CorV by Sinopharm-
BBIBP, and CoronaVac by Sinovac) have been recognized by the World Health Organization for 
emergency use [117]. Recently, the U.S. Food and Drug Administration (FDA) has approved the 
Comirnaty. It is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 12 
years and older. Comirnaty contains a molecule called messenger RNA (mRNA) with instructions for 
producing a protein from SARS-CoV-2, the virus that causes COVID-19. Comirnaty does not 
contain the virus itself and cannot cause COVID-19.Before the advent of any officially approved 
vaccine for use against COVID-19, the first approach of the scientists all over the world was to 
repurpose existing medicines including chloroquine, hydroxychloroquine, favipiravir, interferon, 
lopinavir, nitazoxanide, remdesivir, ribavirin, ritonavir, and umifenovir [118]. But interim results of 
the World Health Organization's SOLIDARITY trial found no significant effect for such drugs on 
COVID-19 patients [119]. In these circumstances, vaccines and other therapeutics agent that are 
being developed are only hope for protecting people from SARS-CoV-2. Many vaccines that are in 
pipeline against COVID-19 are exploiting nanotechnology, because nanostructures can increase the 
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solubility of drugs, cross blood–brain barrier, increase half-life of drugs, decrease toxicity of drugs, 
and in some cases can deliver drug to the target organ and tissue inside the body, thus decreasing the 
toxicity of drugs [120–122]. Nanomaterials such as liposomes, micelles, polymeric nanostructures, 
lipid nanostructures (LNPs), and lipid-polymer hybrid nanostructures have also shown their 
importance for drug delivery [123]. Further, the surfaces of nanostructures can be modified by 
various molecule and functional group for desired biological properties.  
Virus-like particles (VLPs) are a type of lipid-polymer hybrid nanostructures that are derived 
from self-assembly of viral capsid or envelope proteins and are non-infectious because they do not 
contain genetic material and ability to replicate [124,125]. VLPs mimic virus particles and can be 
constructed via recombinant technology to present peptide antigen that could elicit immune response, 
and thus can be used in the development of vaccines [126]. The VLPs can be engineered to display 
antigen or epitope in highly ordered repeating manner, which gives VLPs high immunogenicity that 
can generate strong cellular and humoral immune responses with induction of high affinity 
antibodies [127,128]. Further, VLPs due to its small size range (20–200 nm) [129] can also act as an 
efficient nanoacarrier for foreign (i.e. not related to VLPs itself) antigens that helps them in readily 
taken up by antigen presenting cells to stimulate the immune system [130,131]. 
VLP-based vaccines have been successfully developed against many inflammatory or infectious 
diseases, such as human papillomavirus, hepatitis B virus, etc. [132]. Many companies are 
developing VLPs-based vaccines (some are in clinical phase, while others are in preclinical phase) 
against SARS-CoV-2 (Table 3). 
Medicago Inc, a Canadian company, has utilized plant-derived VLPs with vaccine adjuvants 
from GSK and Dynavax to develop a COVID-19 vaccine [116]. The CoVLP technology utilizes 
Nicotiana benthamiana plant as a bioreactor for the vaccine production by using Agrobacterium 
tumefaciens as disarmed vector that transfer episomal DNA containing SARS CoV-2 spike protein 
gene to the nucleus of the plant cells [133]. Similarly, ARTES Biotechnology is using two VLP-
based technologies—enveloped VLP technology called METAVAX and capsid VLP technology 
called SplitCore—for the development of COVID-19 vaccines [134]. VBI Vaccines Inc. is also 
making COVID-19 vaccine named VBI-2902a using enveloped VLPs as platform, results of which 
recently have been published by Fluckiger and collaborators [135]. The researcher showed 
preliminary efficacy of the vaccine against SARS-CoV-2 in Syrian golden hamsters by suppressing 
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Table 3. Virus-like particles (VLPs) Vaccine against SARS-CoV-2. 
VLPs-based COVID-19 vaccine in clinical development 
Vaccine Developer Trial phase 
CoVLP Medicago; GSK; Dynavax Phase 3 
SARS-CoV-2 VLP Vaccine The Scientific and Technological Research Council of 
Turkey; Dr Abdurrahman Yurtaslan Ankara Oncology 
Training and Research Hospital; MonitorCRO; Nobel 
Pharmaceuticals 
Phase 2 
IVX-411 Icosavax, Inc.; Bill & Melinda Gates Foundation; 
Amgen; Seqirus 
Phase 1/2 
VBI-2902a VBI Vaccines Inc. Phase 1/2 
ABNCoV2 ExpreS2ion Biotech; Bavarian Nordic A/S Phase 1/2 
VLPs-based COVID-19 vaccine in preclinical phase 
Vaccine Developer Country 
VLP Max Planck Institute for Dynamics of Complex 
Technical Systems 
Germany 
Virus-like particle-based  
Dendritic Cell(DC)-targeting vaccine 
University of Manitoba Canada 
VLP Bezmialem Vakif University Turkey 
Enveloped Virus-Like  
Particle (eVLP) 
VBI Vaccines Inc. USA 
S protein integrated in HIV VLPs IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona 
Supercomputing Centre/Grifols 
Spain 
VLP + Adjuvant Mahidol University/ The Government Pharmaceutical 
Organization (GPO)/Siriraj Hospital 
Thailand 
Virus-like particles, lentivirus  
and baculovirus vehicles 
Navarrabiomed, Oncoimmunology group Spain 
Virus-like particle, based on  
RBD displayed on virus-like particles 
Saiba GmbH Switzerland 
ADDomer
TM
 multiepitope display Imophoron Ltd and Bristol University’s Max Planck 
Centre 
UK 
VLP OSIVAX France 
eVLP (enveloped VLP) ARTES Biotechnology Germany 
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VLPs-based COVID-19 vaccine in preclinical phase 
Vaccine Developer Country 
VLPs peptides/whole virus University of Sao Paulo Brazil 
VLPs produced in baculovirus 
expression vector system or BEVS 
Tampere University Finland 
Plant derived VLP Shiraz University Iran 
Myxoma virus co-expressing 
S, M, N and E proteins 
Arizona State University USA 
Plasmid driven production of VLPs 
containing S, M, N and E proteins of 
SARS-CoV-2 
Arizona State University USA 
Virus Like Particle with RCB Berna Biotech Pharma Switzerland 
RBD-HBsAg VLPs or Receptor 
Binding Domain SARS-CoV-2 
Hepatitis B surface antigen VLP 
Vaccine 
SpyBiotech/Serum Institute of India India 
MVA encoded VLP GeoVax/BravoVax China 
Drosophila S2 insect cell expression 
system VLPs 
ExpreS2ion Denmark 
VLP-recombinant protein with 
adjuvant 




encapsulated mRNA cocktail 
encoding VLP 
Fudan University/Shanghai JiaoTong 
University/RNACure Biopharma 
China 
Source: World Health Organization [116]; COVID-19 treatments and vaccine tracker [136] 
Lipid nanostructures (LNPs) are another nanotechnology-based platform that is being used to 
develop vaccines against SARS-Co-2. Most of the mRNA-based COVID-19 vaccines are using lipid 
nanostructures to encapsulate mRNA for delivery into cells. Lipid nanostructures protect mRNA 
against enzymatic degradation, help mRNA in escaping from endosomes and allow release of the 
enclosed mRNA into the cytosol, and improve the cellular uptake and thus expression of mRNA by 
many-fold compared to naked mRNA inside the host cells [137–139]. Among the seven approved 
vaccine for COVID-19 by the World Health Organization [117], two are mRNA based and use lipid 
nanostructures as a nanocarrier for the delivery: Comirnaty (BNT162b2) by Pfizer, BioNTech and 
Fosun Pharma; and Moderna COVID-19 Vaccine (mRNA-1273) by Moderna, Biomedical Advanced 
Research and Development Authority (BARDA), and National Institute of Allergic and Infectious 
Diseases (NIAID). Along with these two, many other mRNA-based vaccines being developed 
against SARS-CoV-2 are using LNPs: ARCoV, CVnCoV, DS-5670a, MRT5500, PTX-COVID19-B, 
and ChulaCov19 (Table 4).  
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Pfizer, in collaboration with BioNTech, has developed the dual-dose vaccine 
Comirnaty
®
BNT162b2 against SARS-CoV-2 [140]. In Comirnaty
®
, nucleoside-modified mRNA—
that encodes receptor binding domain (RBD) of the SARS-CoV-2 spike protein—has been 
encapsulated inside lipid nanostructures. In phase I/II trials in the USA and in Germany, the vaccine 
was found to induce robust immunogenic responses [140]. The UK was the first and Canada was 
second country to approve emergency use of Comirnaty against SARS-CoV-2. To see the efficacy of 
the vaccine among different population groups such as pregnant women over the age of 18, children 
under 12 years old, and adolescents between the age 12 and 15, the clinical trials have been started in 
different countries [140]. With an efficacy of 95%, Comirnaty
®
 has been approved in 85 countries as 
of 16 May 2021 [141]. 
Similarly, Moderna has developed mRNA-1273 vaccine based on lipid nanostructures against 
SARS-CoV-2. The mRNA-1272 vaccine is also two-dosed like as that of Comirnaty
®
 of Pfizer. The 
vaccine exploits lipid nanostructures to encapsulate nucleoside-modified mRNA that encodes SARS-
CoV-2 spike glycoprotein stabilized in its prefusion conformation [142]. In the preliminary studies 
done in mice [142] and primates [143], the vaccine has been found to protect against SARS-CoV-2 
infection. In The Coronavirus Efficacy (COVE) phase 3 randomized, observer-blinded, placebo-
controlled, multicenter trial among 30,420 volunteers in the USA, the mRNA-1273 was found to be 
safe and efficacious for preventing SARS-CoV-2 infection [144]. The Moderna mRNA-1273 vaccine 
has an efficacy of 94.1% and has been approved for use in 46 countries as of 16 May 2021 [141]. 
The other example of COVID-19 vaccine that is using nanostructures platform is NVX-
CoV2373 developed by Novavax. It is a recombinant nanostructure vaccine that displays trimeric 
full-length SARS-CoV-2 spike glycoproteins [145]. Novavax is using its own saponin-based Matrix-
MTM adjuvant technology in the clinical trial for the NVX-CoV2373 vaccine [145]. In the phase 3 
randomized, observer-blinded, placebo-controlled, multicenter trial in the UK, the two-dosed 
regimen of NVX-CoV2373 gave an efficacy of 89.7% against SARS-CoV-2 infection and also found 
to be highly effective against the B.1.1.7 variant [146]. In a recently published research articles, the 
combination of NVX-CoV2373 and recombinant hemagglutinin (HA) quadrivalent nanostructure 
influenza vaccine (qNIV) protected hamsters challenged with SARS-CoV-2 [147]. The combination 
vaccine can also protect against seasons influenza. He et al. [148] have reported a next generation 
vaccine strategy against SARS-CoV-2 using self-assembling protein nanostructures (SApNPs) 
technology. The researchers displayed receptor binding domain (RBD) and SARS-CoV-2 spike as 
vaccine antigens on SApNPs. The nanoparticle system elicited a potent immune response by T-cells 
in mouse model [148].  
In a proof-of-concept study, Zeng's group [149] engineered endogenous untranslated regions (UTRs) 
of mRNAs termed as NASAR to enhance SARS-CoV-2 antigen production. The engineered mRNA 
when delivered using lipid-derived TT3 nanostructures induced improved antibody response in mice 
in comparison with formulation based on FDA-approved lipid nanostructure delivery system. The 
researchers argued for the further development of NASAR system into alternative COVID-19 
vaccines. 
Various research groups have utilized nanostructures such as liposomes, reconstituted 
lipoproteins, and cell-membrane-derived nanostructures that mimick cell membrane to counter 
SARS-Cov-2 infection. These are called nanodecoy or decoy nanostructures. Rao et al. [150] have 
engineered decoy nanostructures to counter SARS-CoV-2. The researchers constructed nanodecoys by 
fusing two types of cell membrane nanovesicles: (1) one derived from human embryonic kidney 293T 
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cells that were genetically engineered to express SARS-CoV-2 receptor ACE2, and (2) another 
derived from human myeloid mononuclear THP-1 cells. The nanodecoys inhibited the replication 
and infection of SARS-CoV-2, and also suppressed immune disorder and lung injury in an acute 
pneumonia mouse model by neutralizing inflammatory cytokines, thus showing potential of 
nanotechnology against COVID-19 [150].  
Li et al. [151] presented the anti-SARS-CoV-2 application of nanodecoys derived from human 
lung spheroid cells (LSCs). The study was done on SARS-CoV-2-infected cynomolgus macaque 
model, which when received nanodecoys via inhalation using a nebulizer showed a reduction of viral 
load and decrease in pulmonary fibrosis. Similarly, Zhang and coworkers [152] prepared two kinds 
of nanosponges (a type of lipid nanostructures) from cell membranes of either human lung epithelial 
type II cells or human macrophages. Because these nanosponges had on their surfaces protein 
receptors used by SARS-CoV-2 for cell entry, they could capture and neutralize SARS-CoV-2 and 
prevent the virus from infecting other host cells.  
Recombinant S1 subunit protein from SARS-CoV-2 was encapsulated in cationic liposomes by 
Liu et al. [153] to prepare a nanovaccine. The vaccine elicited robust humoral responses in mice, and 
the serum from the vaccinated mice significantly inhibited SARS-CoV-2 infection in Vero cells. This 
lipid-based formulation technique presents an interesting approach that can be translated to clinical 
settings to tackle COVID-19. 
Recently, nanobodies, which are highly stable small functional fragment of antibodies, are being 
used as therapeutic agents against many diseases. Canonical antibodies are comprise of two identical 
heavy and two identical light chains, both connected via interchain disulphide bonds and non-
covalent interactions [154]. In comparison, nanobodies lack light chain and also the first constant 
domain (CH1) of the heavy chain, due to which nanobodies can attain compact structure and low 
dimensional size (4 × 2.5 × 3 nm) and low molecular weight (~15 kDa) than that of conventional 
antibodies [155,156]. Nanobodies are naturally found in the camelid family (alpacas, camels, 
dromedaries, guanacos, and llamas) [157]. Nanobodies are highly stable and can easily be produced 
in large quantities in bacterial, yeast, or mammalian expression system [158]. Due to these reasons 
nanobodies are being utilized as therapeutic agents against SARS-CoV-2 infection (Table 5). Many 
studies in in vitro and in vivo conditions have showed strong neutralizing capability of nanobodies 
against SARS-CoV-2 even at nano molar and pico molar range of concentrations (Table 5). 
Nanobodies itself and their derived forms such as nanobody-coated nanostructures and nanobody-
derived nanoprobes have successfully been utilized in imaging, target drug delivery and therapy, and 
diagnosis of diseases [159]. Therefore, nanobodies must be further explored for similar applications 
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Table 4. mRNA-based vaccines using Lipid nanoparticles (LNPs) for the delivery of cargo. 
Vaccine Developer Trial phase 
ARCoV Walvax Biotechnology Co., Ltd.; Abogen Biosciences 
Co. Ltd.; Yuxi Walvax Biotechnology Co., Ltd. 
Phase 3 
CVnCoV CureVac; GSK Phase 2b/3 
DS-5670a Daiichi Sankyo Co., Ltd. Phase 1/2 
MRT5500 Sanofi, Translate Bio Phase 1/2 
LUNAR-COV19 (ARCT-021) Arcturus/Duke-NUS/Catalent Phase 1/2 
LNP-nCoVsaRNA Imperial College Phase 1/2 
(Not named yet) Shanghai Municipal Science and Technology 
Commission; Stemirna Therapeutics 
Phase 1 
(Not named yet) Gritstone Oncology, Inc.; National Institute of Allergic 
and Infectious diseases (NIAID) 
Phase 1 
PTX-COVID19-B Providence Therapeutics; Canadian government Phase 1 
ChulaCov19 Chulalongkorn University Phase 1 
D614G variant LNP        
Encapsulated RNA  
(Bancovid, Banagavax) 
Globe Biotech Ltd Pre-clinical 
LNP-encapsulated  
mRNA encoding S 
Max-Planck-Institute of Colloids and Interfaces Pre-clinical 
Comirnaty (BNT162b2) Pfizer, BioNTech; Fosun Pharma Authorized or 
approved 
Moderna COVID-19 Vaccine 
(mRNA-1273) 
Moderna, Biomedical Advanced Research and  
Development Authority (BARDA), National  
Institute of Allergic and Infectious diseases (NIAID) 
Authorized or 
approved 
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Table 5. Nanobodies against SARS-CoV-2. 
Study Findings Effective inhibitory 
concentration 
Xu et al.  
[160] 
anti-RBD nanobodies isolated from llamas and from engineered 
mice neutralized SARS-CoV-2 variants 
In picomolar  range 
Güttler et al. 
[161] 
The nanobodies bound the open and closed states of the Spike 
protein and interacted tightly with RBD domain. The 
nanobodies were found to be highly thermo stable at 95 ℃ 
17–50 pM 
Sziemel et al. 
[162] 
Recombinant alpaca antibodies neutralized live virus of B.1.351 
variant of concern of SARS-CoV-2 
IC50< 3nM 
Custódio et al. 
[163] 
Nanobodies, Sb23, isolated from a synthetic library, sybodies 
(Sb), targeted the receptor-binding domain (RBD) of the SARS-
CoV-2 spike protein and able to neutralized pseudoviruse 
IC50 of 0.6μg/mL 
Ye et al.  
[164] 
The nanobody Nanosota-1 can bound to the receptor-binding 
domain (RBD) of SARS-CoV-2 spike protein thus blocking out 
ACE2 binding to the RBD. Single dose of Nanosota-1 showed 
therapeutic efficacy in a hamster model of SARS-CoV-2 
infection. 
Neutralization dose 
50% (ND50) of 0.16 
µg/mL 
Pymm et al. 
[158] 
Nanobody cocktails administered prophylactically reduced viral 
loads and infection in mice challenged with the N501Y D614G 
SARS-CoV-2 virus variant 
half-maximal inhibitory 
concentration (IC50) = 
0.1 nM 
Hanke et al. 
[165] 
The alpaca derived nanobody, Ty1, prevented binding of SARS-
CoV-2 RBD to its host cell receptor ACE2. The Ty1 nanobody 
can easily be expressed in bacteria with very high yield 
(>30 mg/L culture) 
IC50 of 0.77 μg/mL 
(54nM) 
Nambulli et al. 
[166] 
Pittsburgh inhalable Nanobody 21 (PiN-21), which can be 
delivered intranasally, prevented and treated SARS-CoV-2 
infection in Syrian hamsters 
0.2 mg/kg 
Esparza et al. 
[167] 
NIH-CoVnb-112 nanobody blocked SARS-CoV-2 spike 
pseudotyped lentivirus infection of HEK293 cells expressing 
human ACE2 
EC50 of 0.3μg/mL 
Xiang et al. 
[168] 
The nanobodies showed very high affinity (~10 pM) with RBD 
of spike protein and able to neutralize pseudotyped SARS-CoV-
2 
half-maximal inhibitory 
concentration as low as 
0.058 ng/mL) 
Koenig et al. 
[169] 
Nanobodies able to neutralize SARS-CoV-2 and SARS-CoV-2–
pseudotyped vesicular stomatitis virus 
IC50 value of 60 nM 
Lu et al.  
[170] 
Nanobodies Nb91-hFc and Nb3-hFc against spike protein and 
its RBD domain neutralized spike pseudotyped viruses in vitro 
IC50 of 1.54 nM 
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5. Conclusions 
The COVID-19 pandemic has created unprecedented challenges for humanity. Nanomaterials 
present interesting candidates that can be incorporated into therapy and diagnostics for SARS-CoV-2. 
Nanomaterials, such as metal nanostructures, graphene and graphene derivatives, nanocomposites, 
and lipid-derived nanomaterials have spawned novel detection methods for COVID-19. Similarly, to 
prevent spread of SARS-CoV-2 in public places and healthcare settings various new products (face 
masks and other personal protective clothings, surface coatings, etc.) based on nanotechnology have 
emerged. However, the claim of such products in controlling the spread of SARS-CoV-2 must be 
properly verified by the appropriate agencies of the respective countries to strengthen the fight 
against COVID-19. Similarly, if any such product is using metal nanostructures, then the toxicity 
analysis of metal nanostructures on human health must be properly assessed. All over the world, 
many research groups are also utilizing nanotechnology for designing vaccines and therapeutic 
agents against SARS-CoV-2. But these efforts have to keep pace with deadlier SARS-CoV-2 variants 
that are continuously emerging from different parts of the world. Further, the findings of research 
studies that used nanotechnology-based approaches against SARS-CoV-2 in lab settings need to be 
translated to clinical settings in humans. This present an attractive opportunity for the scientist 
working in the field of nanotechnology to use their expertise for fighting the COVID-19 pandemic by 
tooth and nail.  
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